Borenstein Nicolas, Bruneval Patrick, Behr Luc, Laborde François, Montarras Didier, Daurès Jean Pierre, Derumeaux Geneviève, Pouchelon Jean-Louis, Chetboul Valérie
IMM Recherche (Centre d'Expérimentation et de Recherche Appliquée) Paris, France.
J Card Surg. 2006 Jan-Feb;21(1):50-6. doi: 10.1111/j.1540-8191.2006.00168.x.
Heart failure in the western world is a major health-care issue. In order to validate novel surgical or pharmacological treatments, reproducible animal models of left ventricular dysfunction are necessary. In the current study, we report our data and experience with a model of toxin-induced heart failure in the sheep.
Sequential intracoronary injections of doxorubicin (0.75 mg/kg) were carried out every 2 weeks until standard echocardiographic and tissue Doppler imaging detection of myocardial systolic dysfunction. The animals were assessed 1 month later and harvested. Indices of cardiac function from baseline to last day of protocol were recorded and their differences were evaluated by a Wilcoxon rank test for paired data.
Ten sheep received 2.5 +/- 0.7 intracoronary injections of a cumulative dose of 88.8 +/- 25 mg/m2 doxorubicin. All available parameters demonstrated signs of severe cardiac dysfunction with statistical significance. All hearts demonstrated severe histological lesions, some of which were consistent with doxorubicin-induced toxicity.
The present study shows that this ovine model is reproducible and stable. It can therefore be relevant to the study of chronic heart failure. It will be incorporated in our future studies concerning novel treatments (such as cell therapy) of nonischemic dilated cardiomyopathy.
在西方世界,心力衰竭是一个重大的医疗保健问题。为了验证新型手术或药物治疗方法,需要可重复的左心室功能障碍动物模型。在本研究中,我们报告了我们在绵羊毒素诱导性心力衰竭模型方面的数据和经验。
每2周进行一次阿霉素(0.75mg/kg)冠状动脉内注射,直至通过标准超声心动图和组织多普勒成像检测到心肌收缩功能障碍。1个月后对动物进行评估并宰杀。记录从基线到实验方案最后一天的心脏功能指标,并通过配对数据的Wilcoxon秩和检验评估其差异。
10只绵羊接受了2.5±0.7次冠状动脉内注射,阿霉素累积剂量为88.8±25mg/m²。所有可用参数均显示出严重心脏功能障碍的迹象,具有统计学意义。所有心脏均显示出严重的组织学损伤,其中一些与阿霉素诱导的毒性一致。
本研究表明,这种绵羊模型具有可重复性和稳定性。因此,它可能与慢性心力衰竭的研究相关。它将被纳入我们未来关于非缺血性扩张型心肌病新治疗方法(如细胞治疗)的研究中。